Metastatic breast cancer: Bevacizumab slows progression, but has no impact on survival

The cancer drug bevacizumab (Avastin) offers only a modest benefit in delaying disease progression in patients with advanced stage breast cancer, according to a systematic review by Cochrane researchers. The researchers assessed the efficacy of bevacizumab in combination with chemotherapy, an established cancer treatment in this indication, and found no overall survival benefit when adding bevacizumab to chemotherapy.

is the most common cause of among women. If it spreads to other parts of the body it is referred to as "metastatic" and the cancer becomes much more difficult to treat. One promising approach is drugs that target vascular endothelial growth factor (VEGF), a key molecule mediating growth of blood vessels in tumours. At present, trials of drugs that target VEGF are limited to bevacizumab, which is the first drug of this type to be approved for metastatic breast cancer.

To assess the clinical value of bevacizumab in combination with other established chemotherapy drugs, the researchers gathered evidence from seven trials involving a total of 4,032 patients, most of whom had metastatic breast cancer. They found that adding bevacizumab to established drug regimens increased the time to tumour progression or death by between one and six months, depending on the prescribed. However, the researchers found that adding bevacizumab to first- or second-line treatments did not increase overall survival or quality of life.

"At best, adding bevacizumab to standard chemotherapy appears to offer a modest benefit for those with metastatic breast cancer," said lead researcher, Anna Dorothea Wagner, of the Fondation du Centre Pluridisciplinaire d'Oncologie, University Hospital Lausanne, Switzerland. "Whether it can truly be of benefit to the patient is debatable, because it only briefly prolongs progression of the disease. No impact on the patient's overall survival or quality of life has been demonstrated."

According to the researchers, clinical trials testing new drugs for advanced stage breast cancer should follow patients until death in order to understand the impact of new treatments on survival. "The fact that an increase in progression-free survival does not lead to an increase in overall survival suggests that progression-free survival may not be a reliable surrogate for clinical trials in metastatic cancer," said Wagner.

In 2011, the US Food and Drug Administration (FDA) removed breast cancer from indications on the label of , due to concerns about serious side effects and doubts about its benefit in terms of overall survival. By contrast, it is approved for first-line treatment of metastatic breast cancer in Europe, in combination with the cancer drug paclitaxel, as well as in combination with capecitabine for patients with metastatic cancer who are not eligible for treatment with taxanes or anthracyclines.

More information: Wagner AD, Thomssen C, Haerting J, Unverzagt S. Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer. Cochrane Database of Systematic Reviews 2012, Issue 7. Art. No.: CD008941. DOI: 10.1002/14651858.CD008941.pub2

add to favorites email to friend print save as pdf

Related Stories

US revokes Roche's Avastin for breast cancer

Nov 18, 2011

US health officials on Friday revoked the authorization of Roche's Avastin for breast cancer treatment, saying it concluded the drug had "not been shown to be safe and effective for that use."

Recommended for you

Study pinpoints microRNA tied to colon cancer tumor growth

9 hours ago

Researchers at the University of Minnesota have identified microRNAs that may cause colon polyps from turning cancerous. The finding could help physicians provide more specialized, and earlier, treatment before colon cancer ...

Obesity tied to higher cancer risk for CRC survivors

10 hours ago

(HealthDay)—Colorectal cancer (CRC) patients who are overweight or obese when diagnosed appear to face a slightly higher risk for developing a second weight-related cancer, according to research published ...

User comments